87 Effects of prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC); results of UKCCCR/EORTC randomised trial

• Published in: European journal of cancer (1990) 1995-11, Vol.31, p.S20-S20
• Main Authors: Gregor, A., Cull, A., Stephens, R.J., Macbeth, F.R., Thatcher, N.
• Format: Article
• Language: English
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(95)95339-8

This multicentre randomised trial was designed to assess the effect of PCI on survival, appearance of cranial metastasis and cognitive function in patients with limited disease and complete response (CR) to induction treatment. At the time of the abstract submission 299 of the planned 300 patients have been randomised. Ninety-seven patients undergone prospective neuropsychometric assessment. All patients received initial chemotherapy and 84% also had thoracic irradiation. Median age at the time of randomisation was 60 (range 28–79) and 64% were male. The current median survival from randomisation is 10 months (95% confidence interval 9–12 months) with estimated survival 43% at one year, 23% at 2 years and 18% at three years from randomisation. Sixty-four patients have been reported as having cranial relapse, KM estimates being 29% at one year, 37% at 2 years and 42% at 3 years from randomisation. The analysis presented at the meeting will include comparisons of rates of survival, cranial metastases and cognitive function between the randomised PCI or no PCI groups at a time when the trial will have been closed for 6 months and 90% of patients will be more than 1 year from randomisation.